{"transactions":[{"id":1175878,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":80995,"kind":"organization","name":"TPAV, LLC","position":1,"cik":"0002017798","reported_name":"TPAV, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":2,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Series C Preferred Stock","published_at":"2025-04-09T00:32:34.000Z","date":"2025-04-02","kind":"other","planned":false,"acquired":false,"shares":2263.7451,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series C Preferred Stock is convertible into 400 shares of the Issuer's common stock, subject to an issuance limitation that prohibits the holder from converting such shares of Series C Preferred Stock to the extent that, after giving effect to the issuance of shares of common stock after such conversion, the holder (together with the holder's affiliates and any other persons acting as a group together with the holder or any of the holder's affiliates) would beneficially own in excess of 19.99% of the shares of common stock of the Issuer then outstanding (the \"Beneficial Ownership Limitation\")."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 2, 2025, the TPAV, LLC (\"TPAV\") disposed of all of the shares of the Issuer's Common Stock and Series C Non-Voting Convertible Preferred Stock (\"Series C Preferred Stock\") held by TPAV as of such date through a pro rata distribution of such shares to its members, including Nikolay Savchuk. No consideration was paid in connection with such distribution. As a result of the distribution, TPAV is no longer a 10% owner, and therefore is no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer and will no longer report any such transactions on Form 4 or Form 5. Mr. Savchuk will continue to be subject to Section 16."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 2, 2025, the TPAV, LLC (\"TPAV\") disposed of all of the shares of the Issuer's Common Stock and Series C Non-Voting Convertible Preferred Stock (\"Series C Preferred Stock\") held by TPAV as of such date through a pro rata distribution of such shares to its members, including Nikolay Savchuk. No consideration was paid in connection with such distribution. As a result of the distribution, TPAV is no longer a 10% owner, and therefore is no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer and will no longer report any such transactions on Form 4 or Form 5. Mr. Savchuk will continue to be subject to Section 16."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Following stockholder approval of the conversion of the Series C Preferred Stock into shares of the Issuer's common stock, which was obtained on September 16, 2024, the shares of Series C Preferred are convertible into shares of common stock, subject to the Beneficial Ownership Limitation."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The Series C Preferred Stock do not expire."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"On September 16, 2024, the Issuer's Board of Directors approved a one-for-twenty-five reverse stock split, which was effective on September 20, 2024. All shares of the Issuer's common stock and all shares of the Issuer's Series C Preferred Stock (\"Series C Preferred Stock\") reported in this Form 4 are presented on an after-reverse stock split basis."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Mr. Savchuk is the sole manager on the Board of Managers of TPAV and also owns a 31% interest in TPAV. As a result of the distribution discussed in footnote 1 hereof, Mr. Savchuk received 170,710 shares of common stock of the Issuer and 638.1904 shares of Series C Preferred Stock of the Issuer and now owns those shares directly."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":905497},"source":{"system":"sec-edgar","filing":"0001104659-25-033149","document":"tm2511901-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925033149/tm2511901-1_4seq1.xml","form_type":"4"}},{"id":1175877,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":80995,"kind":"organization","name":"TPAV, LLC","position":1,"cik":"0002017798","reported_name":"TPAV, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":30381,"kind":"person","name":"Savchuk Nikolay","position":2,"cik":"0002017800","reported_name":"Savchuk Nikolay","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-04-09T00:32:34.000Z","date":"2025-04-02","kind":"other","planned":false,"acquired":false,"shares":605531,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 2, 2025, the TPAV, LLC (\"TPAV\") disposed of all of the shares of the Issuer's Common Stock and Series C Non-Voting Convertible Preferred Stock (\"Series C Preferred Stock\") held by TPAV as of such date through a pro rata distribution of such shares to its members, including Nikolay Savchuk. No consideration was paid in connection with such distribution. As a result of the distribution, TPAV is no longer a 10% owner, and therefore is no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer and will no longer report any such transactions on Form 4 or Form 5. Mr. Savchuk will continue to be subject to Section 16."},{"field":"shares","element":"transactionShares","label":"F2","text":"On September 16, 2024, the Issuer's Board of Directors approved a one-for-twenty-five reverse stock split, which was effective on September 20, 2024. All shares of the Issuer's common stock and all shares of the Issuer's Series C Preferred Stock (\"Series C Preferred Stock\") reported in this Form 4 are presented on an after-reverse stock split basis."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 2, 2025, the TPAV, LLC (\"TPAV\") disposed of all of the shares of the Issuer's Common Stock and Series C Non-Voting Convertible Preferred Stock (\"Series C Preferred Stock\") held by TPAV as of such date through a pro rata distribution of such shares to its members, including Nikolay Savchuk. No consideration was paid in connection with such distribution. As a result of the distribution, TPAV is no longer a 10% owner, and therefore is no longer subject to Section 16 in connection with its transactions in the equity securities of the Issuer and will no longer report any such transactions on Form 4 or Form 5. Mr. Savchuk will continue to be subject to Section 16."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Mr. Savchuk is the sole manager on the Board of Managers of TPAV and also owns a 31% interest in TPAV. As a result of the distribution discussed in footnote 1 hereof, Mr. Savchuk received 170,710 shares of common stock of the Issuer and 638.1904 shares of Series C Preferred Stock of the Issuer and now owns those shares directly."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-25-033149","document":"tm2511901-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925033149/tm2511901-1_4seq1.xml","form_type":"4"}},{"id":1294696,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":80995,"kind":"organization","name":"TPAV, LLC","position":1,"cik":"0002017798","reported_name":"TPAV, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrant (right to buy)","published_at":"2025-01-28T00:01:45.000Z","date":"2024-12-29","kind":"purchase","planned":false,"acquired":true,"shares":96348,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series A Warrants shall become exercisable on June 30, 2025; provided however, that the Series A Warrants may not be exercised prior to the issuer's receipt of stockholder approval of the exercise of the Series A Warrants, in accordance with Nasdaq listing rules."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Series A Warrants shall expire on the date that is the earlier of (a) December 31, 2029, and (b) subject to the fulfilment of certain equity conditions, thirty trading days after the last of the following data readouts to occur, as announced by the issuer: (i) Ferret animal model Bird Flu data, (ii) non-human primate Bird Flu data, or (iii) Phase 2a Influenza A human clinical data."}],"balance_after":96348,"derivative":{"exercise_price":13.42,"underlying":"Common Stock","underlying_shares":96348},"source":{"system":"sec-edgar","filing":"0001104659-25-006407","document":"tm254427d2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925006407/tm254427d2_4seq1.xml","form_type":"4"}},{"id":1294695,"issuer":{"id":8032,"kind":"organization","name":"Traws Pharma, Inc."},"owners":[{"id":80995,"kind":"organization","name":"TPAV, LLC","position":1,"cik":"0002017798","reported_name":"TPAV, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Warrant (right to buy)","published_at":"2025-01-28T00:01:45.000Z","date":"2024-12-29","kind":"purchase","planned":false,"acquired":true,"shares":96348,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Pre-Funded Warrants and Series A Warrants were purchased as part of Class B Units, with each Class B Unit consisting of one Pre-Funded Warrant and one Series A Warrant, at a purchase price of $5.093 per Class B Unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Pre-Funded Warrants shall become exercisable upon stockholder approval of the exercise of the Pre-Funded Warrants, in accordance with Nasdaq listing rules."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Pre-Funded Warrants do not expire."}],"balance_after":96348,"derivative":{"exercise_price":0.01,"underlying":"Common Stock","underlying_shares":96348},"source":{"system":"sec-edgar","filing":"0001104659-25-006407","document":"tm254427d2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1130598/000110465925006407/tm254427d2_4seq1.xml","form_type":"4"}}]}